The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 375.00
Bid: 370.00
Ask: 380.00
Change: 5.00 (1.37%)
Spread: 10.00 (2.703%)
Open: 365.00
High: 370.00
Low: 370.00
Prev. Close: 365.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Increase to Block Listing

21 Jan 2021 14:49

RNS Number : 5100M
MaxCyte, Inc.
21 January 2021
 

 

 

 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

 

Increase to Block Listing,

 

Block Listing Return

 

and

 

Total Voting Rights

 

 

 

MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announces that application has been made for admission to trading on AIM in respect of an additional block listing of 942,900 common stock of $0.01 each in the capital of the Company ("Common Stock") to become effective on 27 January 2021.

 

The Common Stock may be issued pursuant to the exercise of share options under the Company's Long-Term Incentive Plan (the "LTIP") and will, upon issue, rank pari passu in all respects with the Company's existing Common Stock. Following this increase, the total Block Listing will consist of 1,000,000 Common Stock.

 

 

AIM Block Admission Return

 

MaxCyte also makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.  

 

a. Name of company

 

MaxCyte, Inc.

 

b. Name of scheme(s)

 

MaxCyte Long Term Incentive Plan

 

c. Period of return:

 

From: 1 July 2020 To: 21 January 2021

 

d. Number and class of securities not issued under scheme

 

319,263 ordinary shares of common stock of $0.01 each

 

e. Number of shares issued under scheme during period

 

262,163 ordinary shares of common stock of $0.01 each

 

f. Balance under the scheme not yet issued at the end of the period.

 

57,100 ordinary shares of common stock of $0.01 each

 

g. Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission; If additional block listing application have been made, under this scheme, since the original listing application please also state the number of shares and the date(s) of admission.

 

1,000,000 ordinary shares of common stock of $0.01 each on 5 May 2017

 

Please confirm your total issued share capital as at the end of this period.

(If you hold any shares in Treasury state the figure separately);

 

 

The total issued stock capital of the Company is 77,422,169 shares of Common Stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 67,522,080 and the number of restricted shares of Common Stock trading under the symbol 'MXCS' is 9,900,089.  

 

 

Treasury shares (if applicable) ………Nil………….

 

h. Contact name and telephone number for queries;

 

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Accounting Officer

+1 301 944 1660

 

Date

 

21 January 2021

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRPPUMCGUPGGCG
Date   Source Headline
8th May 20247:05 amRNSFiling of Form 10-Q
8th May 20247:00 amRNSFirst Quarter Results
3rd May 20247:00 amRNSNotice of AGM
1st May 20245:04 pmRNSTotal Voting Rights
10th Apr 20241:05 pmRNSNotice of Results
3rd Apr 20247:00 amRNSTotal Voting Rights and Block Listing Return
2nd Apr 20241:05 pmRNSSigning of Strategic Platform License
2nd Apr 20247:00 amRNSExercise of options and PDMR dealing
20th Mar 202410:16 amRNSGrant of Options, RSUs and PSUs and PDMR Dealing
20th Mar 202410:05 amRNSGrant of Options, RSUs and PSUs and PDMR Dealing
13th Mar 20247:05 amRNSFiling of form 10-K for FY ended December 31, 2023
13th Mar 20247:00 amRNSReports Q4 & FY 2023 Financial Results
6th Mar 20248:58 amRNSTR-1: Notification of major holdings
5th Mar 20247:00 amRNSPreliminary FY Results & 2024 Guidance
1st Mar 20245:57 pmRNSTotal Voting Rights
29th Feb 20249:21 amRNSExercise of options and PDMR dealing
26th Feb 20247:00 amRNSTR-1: Notification of major holdings
9th Feb 20241:05 pmRNSNotice of Results
1st Feb 20249:24 amRNSTotal Voting Rights
31st Jan 20247:00 amRNSDirector/PDMR Shareholding
30th Jan 20242:29 pmRNSHolding(s) in Company
30th Jan 20241:05 pmRNSSigning of Strategic Platform License
29th Jan 20244:52 pmRNSTR-1: Notification of major holdings
29th Jan 20247:00 amRNSFiling of Form 8-K
23rd Jan 20241:05 pmRNSSigning of Strategic Platform License
9th Jan 20247:00 amRNSPreliminary Unaudited Q4 and FY 2023 Results
5th Jan 20247:00 amRNSGrant of Options and PDMR Dealing
3rd Jan 20241:05 pmRNSSigning of Strategic Platform License
2nd Jan 20249:23 amRNSTotal Voting Rights
2nd Jan 20247:00 amRNSConfirmation of Board change
29th Dec 20237:00 amRNSExercise of options and PDMR dealing
12th Dec 20237:00 amRNSCEO Transition and Revenue Guidance Update
7th Dec 20239:50 amRNSExercise of options and PDMR dealing
4th Dec 20237:00 amRNSExercise of options and PDMR dealing
1st Dec 20235:43 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of options and PDMR dealing
17th Nov 20237:00 amRNSExercise of options and PDMR dealing
16th Nov 20231:05 pmRNSMaxCyte Joins the Alliance for mRNA Medicines
9th Nov 20237:01 amRNSFiling of Form 10-Q
9th Nov 20237:00 amRNSThird Quarter Results
7th Nov 20237:00 amRNSParticipation in Upcoming Investor Conferences
1st Nov 20231:12 pmRNSTotal Voting Rights
5th Oct 20237:00 amRNSPreliminary Q3 Revenue & FY Revenue Guidance
2nd Oct 20234:03 pmRNSTotal Voting Rights
13th Sep 20232:28 pmRNSTR-1: Notification of major holdings
12th Sep 20231:21 pmRNSTR-1: Notification of major holdings
5th Sep 20234:17 pmRNSTR-1: Notification of major holdings
5th Sep 20231:05 pmRNSBaird Global Healthcare Conference Participation
4th Sep 20231:32 pmRNSTR-1: Notification of major holdings
4th Sep 20237:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.